1 AMPH stock price continued to rise since May after a long phase of consolidation. 2 Amphastar Pharmaceuticals earnings constantly pushed the stock price in the past. Amphastar Pharmaceuticals (NASDAQ: AMPH) stock price is trading at its all time high price since its listing. Th...
- 1 AMPH stock price continued to rise since May after a long phase of consolidation.
- 2 Amphastar Pharmaceuticals earnings constantly pushed the stock price in the past.
Amphastar Pharmaceuticals (NASDAQ: AMPH) stock price is trading at its all time high price since its listing. The small cap company within the pharmaceutical space is among the leading ones within the space. The mid-cap companies become a preferable choice if they bring considerable return, which is a no brainer.
The broader medical sector lost 0.57% value in the last intraday session when Amphastar stock price gained up to 1.50%. Tech-heavy NASDAQ dropped 2% in the similar time frame and the S&P 500 Pharmaceuticals Industry Index was 3% down.
Amphastar Pharmaceuticals $500M Deal With Lilly
In April, the company came into an agreement with a giant player in the pharma sector, Eli Lilly and Co (NYSE: ELI). Amphastar was reported to acquire Baqsimi nasal spray from Lilly in a deal worth $500 Million cash and additional $125 Million to be paid within a year of the deal.
Though the deal was significantly big for Amphastar given the company’s small-cap size, it decided to go all in with the available cash and senior credit facility. The deal to acquire the nasally administered product, which generated $139.3 Million in revenue last year, did not bring enthusiasm to the investors and the AMPH stock price had to suffer.
Ever Getting Better Earnings for Amphastar Pharmaceuticals
Amphastar Pharmaceuticals reported a revenue of $140.02 Million, 2% more than the estimated revenue of $137.2 Million. The company reported earnings per share (EPS) of $0.62, 16% up from the expected EPS of $0.53.
The company had been doing well in terms of revenue and EPS for the past several years. In the longer time frame, AMPH stock price increased over 250% in the last five years while the company turned profitable in the recent three years. For this latter part, on an average Amphastar EPS grew by 20% and revenue by 16% annually every year.
Amphastar Pharmaceuticals (AMPH) Stock Price Movement
AMPH stock has been moving up since the last earnings report of the first quarter of 2023 in May. The stock price of the drug maker company has been trading in an uptrend since then. It has gained nearly 75% of its value within less than three months.
Prior to the support from above $35, Amphastar share price was in a downtrend during April. Following the announcement of a deal with Lilly to acquire Baqsini, AMPH stock price fell up to 6% in a day and over 18% in the coming 4 days. However, the better than estimated earnings acted as damage control.
Currently, the AMPH stock price is above the 50- and 200-day EMA and the gap between both the exponential moving-averages is ever broadening. MACD is above the zero-line and signifies a crossover, suggesting a bullish move ahead. RSI is at 68 indicating the stock is about to enter the overbought zone, so a slight retracement could be expected.
Disclaimer
The views and opinions stated by the author, or any people named in this article, are for informational purposes only and do not establish financial, investment, or other advice. Investing in or trading crypto assets comes with a risk of financial loss.